You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer

  • Technology appraisal guidance
  • Reference number: TA424
  • Published:  21 December 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 Evidence
  • 4 Committee discussion
  • 5 Implementation
  • 6 Appraisal committee members and NICE project team

3 Evidence

The appraisal committee (section 6) considered evidence submitted by Roche and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.


Next page 4 Committee discussion Previous page 2 The technology
Back to top